Titlebook: Renal Cell Carcinoma; Molecular Targets an Ronald M. Bukowski,Robert A. Figlin,Robert J. Motz Book 2015Latest edition Springer Science+Busi

purulent

書(shū)目名稱(chēng)Renal Cell Carcinoma影響因子(影響力)




書(shū)目名稱(chēng)Renal Cell Carcinoma影響因子(影響力)學(xué)科排名




書(shū)目名稱(chēng)Renal Cell Carcinoma網(wǎng)絡(luò)公開(kāi)度




書(shū)目名稱(chēng)Renal Cell Carcinoma網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書(shū)目名稱(chēng)Renal Cell Carcinoma被引頻次




書(shū)目名稱(chēng)Renal Cell Carcinoma被引頻次學(xué)科排名




書(shū)目名稱(chēng)Renal Cell Carcinoma年度引用




書(shū)目名稱(chēng)Renal Cell Carcinoma年度引用學(xué)科排名




書(shū)目名稱(chēng)Renal Cell Carcinoma讀者反饋




書(shū)目名稱(chēng)Renal Cell Carcinoma讀者反饋學(xué)科排名

Panacea

978-1-4939-5063-8Springer Science+Business Media New York 2015

阻塞

http://image.papertrans.cn/r/image/826986.jpg

Fraudulent

Targeted Therapy for Metastatic Renal Cell Carcinoma: Introduction,ular targets identified in RCC. The ongoing evolution of this new treatment paradigm and development of multiple targeted agents with significant clinical activity in patients with advanced clear-cell carcinoma prompted this undertaking. Additionally, recent data investigating the molecular effects

鬼魂

Renal Cell Carcinoma: Pathologic and Molecular Assessment of Targets,dered lipomas, originated in the neoplastic transformation of adrenal cortical residues into renal cortical. One year later, he confirmed his theory when he found ectopic adrenal cortex in the renal cortex. This theory was readily opposed by Sudek, who favored a renal tubular origin. The controversy

過(guò)多

個(gè)人長(zhǎng)篇演說(shuō)

Champion

PBRM1: A Critical Subunit of the SWI/SNF Chromatin Remodeling Complex, cancer biomarkers. Also, they have triggered intensive efforts in basic science laboratories to elucidate the biological function behind each enigmatic gene, with a view toward refining paradigms that more accurately reflect ccRCC formation and disease progression, and for developing better strateg

鋼盔

Sporadic RCC: Abnormalities in Histone-Modifying Genes,Oncol Hematol 88(1):42–56, 2013). The elucidation of VHL function and mTOR pathway activation led to the discovery of VEGF and mTOR inhibitors for RCC treatment. Recently, secondary mutations identified in histone-modifying enzymes suggest that chromatin remodeling and alterations of histone modific

刺耳